Could fewer plasma exchange sessions be just as effective for kids with brain inflammation?

NCT ID NCT07707739

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial tests whether plasma exchange (a blood-cleaning procedure) given every other day works as well as daily sessions for children with autoimmune encephalitis, a condition where the immune system attacks the brain. The study involves 22 children who are randomly assigned to one of the two schedules. The main goal is to see if both groups achieve similar improvements in daily functioning, measured by a standard disability scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Plasma exchange (PLEX) sessions
What this could lead to
If this trial succeeds, it could show that alternate-day plasma exchange works as well as daily sessions, reducing treatment burden for children with autoimmune encephalitis.
What could go wrong
This is a small, early-stage trial with only 22 participants, so results may not apply broadly. The study does not compare against no treatment or other therapies, limiting its impact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ENCEPHALITIS (AE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Menoufia university hospital, Pediatric intensive care unit

    Shibīn al Kawm, Menoufia Governorate, Egypt

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.